AR and breast cancer: Regarding RNF220 upregulation, multi-database analysis identified FOXA1 as a negative transcriptional regulator—this epigenetic modulator directly binds androgen receptor promoters (43), serves as an ER+ breast cancer biomarker (44), and drives progression in prostate/breast cancers via mutational activation (45–47).